Glenmark Pharma Share Price Rises 3% After DCGI Nod for Phase 3 Trial of Envafolimab

On Friday, September 5, 2025, Glenmark Pharmaceuticals share price (NSE: GLENMARK) rose as much as 3.24% to hit an intraday high of ₹2,055.15. Around 11:20 AM, the stock was trading at ₹2,051.40, up 3.05%, even as the BSE Sensex slipped 0.25% to 80,518.51 levels.

Why Did Glenmark Share Price Rise?

The stock rally came after Glenmark received approval from the Drugs Controller General of India (DCGI) to begin Phase 3 clinical trials of Envafolimab, a new subcutaneous PD-L1 inhibitor, for patients with resectable Stage III non-small cell lung cancer (NSCLC).

Details of the Phase 3 Trial

• The study will be conducted across multiple countries (excluding China).
• It will test the safety, efficacy, pharmacokinetics, and immunogenicity of Envafolimab.
• Enrollment and dosing will start in India, with trials also planned in Russia, Brazil, and Mexico.
• In China, Phase 3 trials of the drug are already underway by 3D Medicines Inc.

Company Statement

Monika Tandon, Global Head of Clinical Development at Glenmark, said this trial is a key milestone in oncology. She highlighted that the subcutaneous delivery of Envafolimab could make immunotherapy more accessible and convenient for patients, especially in regions with limited healthcare resources.

Also Read: Kalyan Jewellers Net Profit Rises 48.6% to ₹264 Crore!

Industry Context

• Lung cancer is the leading cause of cancer deaths globally.
• NSCLC accounts for 85% of all lung cancer cases.
• Survival rates for Stage III patients remain very low, creating a huge need for innovative treatments.

About Glenmark

Glenmark is a research-driven global pharma company with businesses in branded drugs, generics, and OTC products. It operates in 80+ countries and runs 11 manufacturing facilities across four continents.

Conclusion

Glenmark Pharma’s Phase 3 trial approval for Envafolimab is a major step forward in its oncology pipeline. The stock’s rally shows strong investor confidence in its potential to bring innovative cancer therapies to market, especially in treating Stage III NSCLC, where current survival rates remain poor.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.